Form 4: Adverum Biotechnologies Director, Szilard Kiss, Acquires 21,040 Stock Options

Szilard Kiss, a director of Adverum Biotechnologies, acquired 21,040 stock options on June 17, 2024, as reported in a Form 4 filing with the SEC.

Summary

• On June 17, 2024, Szilard Kiss, a director of Adverum Biotechnologies, Inc., was granted 21,040 stock options.
• The exercise price of these options is $7.32 per share.
• The options vest in three equal annual installments starting on June 17, 2024, subject to continued service and accelerated vesting upon a change of control.
• The options expire on June 16, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director, which is a common practice.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded biotechnology companies.
• The vesting schedule of three years is typical for such grants, aligning with industry norms for incentivizing long-term performance.
• Comparable companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates